A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06295692 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions

DRUG: JNJ-77242113

Sponsor

Janssen Pharmaceutical K.K.